Core Viewpoint - The stock of Jinfang Pharmaceutical-B (02595) experienced significant volatility, initially dropping over 8% before recovering to a gain of 6.71%, trading at 28.3 HKD with a transaction volume of 44.52 million HKD. This fluctuation is linked to the announcement of a clinical trial for their KRAS G12D inhibitor GFH375, which has garnered attention due to its potential in treating advanced solid tumors [1]. Group 1 - Jinfang Pharmaceutical announced the initiation of an Ib/II phase clinical trial for GFH375, a small molecule KRAS G12D inhibitor, in combination therapies for KRAS G12D mutant advanced solid tumors [1]. - The trial received approval from the National Medical Products Administration in September 2023 and involves combination therapies with cetuximab or chemotherapy, with GFH375 being part of the first-line treatment for pancreatic ductal adenocarcinoma (PDAC) [1]. - Data from GFH375's monotherapy for KRAS G12D mutant PDAC patients was presented at the 2025 ESMO annual meeting, highlighting its efficacy and safety [1]. Group 2 - The oral presentation at the ESMO meeting was conducted by Professor Zhou Aiping from the Chinese Academy of Medical Sciences, focusing on the efficacy and safety of GFH375 in a specific dosage group of PDAC patients [1]. - The study emphasized the promising results of GFH375 treatment, showcasing its potential as a significant therapeutic option for patients with advanced KRAS G12D mutant PDAC [1].
劲方医药-B由跌转涨逾9% GFH375联合疗法治疗晚期实体瘤研究完成首例入组